Gaboxadol: Difference between revisions

Line 2:

'''''~~Gaboxadol~~''''' is a [[depressant]] substance of the [[isoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}

'''Gaboxadol''' (also knows as '''THIP''', '''OV101''' and '''LU-2-030''') is a [[depressant]] substance of the [[isoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}

It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen. Since then it was subject to numerous medical evaluations for potential applications as an anxiolytic and hypnotic as well as treating conditions such as Alzheimer's disease among others. It's latest attempt at clinical trials was for the treatment of insomnia, although the trials have been cancelled.<ref>http://harpers.org/archive/2013/08/gaboxadol/</ref><ref>US Patent 4278676 - Heterocyclic compounds</ref>

@@ Line 2: / Line 2: @@
 {{SummarySheet}}
-'''''Gaboxadol''''' is a [[depressant]] substance of the [[isoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}
+'''Gaboxadol''' (also knows as '''THIP''', '''OV101''' and '''LU-2-030''') is a [[depressant]] substance of the [[isoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}
 It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen. Since then it was subject to numerous medical evaluations for potential applications as an anxiolytic and hypnotic as well as treating conditions such as Alzheimer's disease among others. It's latest attempt at clinical trials was for the treatment of insomnia, although the trials have been cancelled.<ref>http://harpers.org/archive/2013/08/gaboxadol/</ref><ref>US Patent 4278676 - Heterocyclic compounds</ref>